InvestorsHub Logo
Followers 28
Posts 2714
Boards Moderated 0
Alias Born 10/29/2007

Re: None

Thursday, 02/29/2024 10:18:28 AM

Thursday, February 29, 2024 10:18:28 AM

Post# of 350
Patents Assigned to Oncolytics Biotech, Inc. till 2020, 2021-24 newly filed list not yet public
https://patents.justia.com/assignee/oncolytics-biotech-inc
2024 Outlook: Dr. Coffey: Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer. The transition to a late-stage biopharmaceutical company will mark an important inflection point for investors, clinical collaborators and potential partners by providing a line of sight towards the path to regulatory approval and achieving our mission of developing pelareorep as an immunotherapeutic agent for cancer. We are excited to launch a new Phase 1/2 pancreatic cancer study investigating, for the first time, pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX). Finally, our discussions with regulators on a pivotal Phase 3 trial have been productive to date, and we expect to provide guidance on the registration path for metastatic breast cancer in the first half of 2024. We look forward to updating our stakeholders on our progress as the year unfolds."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCY News